Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A PHASE-II STUDY OF HIGH-DOSE HYDROXYUREA AND DACARBAZINE (DTIC) IN THE TREATMENT OF METASTATIC MALIGNANT-MELANOMA
Autore:
PHILIP PA; CARMICHAEL J; TONKIN K; GANESAN TA; HARRIS AL;
Indirizzi:
CHURCHILL HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT OXFORD OX3 7LJ ENGLAND CHURCHILL HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT OXFORD OX3 7LJ ENGLAND
Titolo Testata:
European journal of cancer
fascicolo: 7, volume: 30A, anno: 1994,
pagine: 1027 - 1029
SICI:
0959-8049(1994)30A:7<1027:APSOHH>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
DNA; CHEMOTHERAPY; INVIVO; REPAIR;
Keywords:
HYDROXYUREA; DACARBAZINE; MELANOMA; DNA REPAIR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
14
Recensione:
Indirizzi per estratti:
Citazione:
P.A. Philip et al., "A PHASE-II STUDY OF HIGH-DOSE HYDROXYUREA AND DACARBAZINE (DTIC) IN THE TREATMENT OF METASTATIC MALIGNANT-MELANOMA", European journal of cancer, 30A(7), 1994, pp. 1027-1029

Abstract

Dacarbazine (DTIC) exerts its major biochemical effect through the formation of methylated DNA adducts. Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides. Combination of HU and DTIC was used to enhance the activity of DTIC by inhibiting DNA repair. 16 patients with metastatic malignant melanoma were treated with the combination. All patients had measurable disease and none had received prior systemic therapy. Hydroxyurea was given as a continuous intravenous (i.v.)infusion of 1 g/h (total 36 g) and DTIC 1 g/m(2) i.v. over 1 h, 23 h from the start of hydroxyurea infusion. 4 patients achieved partial remission with an objective remission rate of 25% [95% confidence interval (CI) 7-52%]. Median duration of response was 3.5 months. 3 of the responding patients had predominant visceral metastases. Disease was stabilised in 5 patients with a median time to progression of 16 months. The predominant toxicity to this treatment was gastrointestinal, with3 patients developing grade 3 nausea/vomiting. Only 1 patient developed grade 3 leucopenia complicated by septicaemia. It is concluded thatthe combination of hydroxyurea and DTIC is a well-tolerated regimen with activity against visceral metastases from malignant melanoma but the duration of response to this treatment is short.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 04:05:28